“I can verify we have submitted information on the efficacy of the vaccine in 12 to fifteen years olds for overview by U.Ok. MHRA,” the spokesman informed Reuters by e-mail. The transfer comes a day after U.S. regulators authorised the vaccine made by Pfizer and BioNTech SE to be used in youngsters as younger as 12.
In March, Pfizer and BioNTech stated their Covid-19 vaccine was protected, efficient and produced sturdy antibody responses in 12- to 15-year olds, citing a trial of two,260 adolescents, which resulted in 100% efficacy in stopping the sickness.
Pfizer has stated it expects to have security and efficacy information on the vaccine for kids aged 2 to 11 in September when it plans to ask for that age group to be included within the emergency authorisation.
The Telegraph earlier reported that Pfizer had requested Britain’s Medicines and Healthcare merchandise Regulatory Company for approval of the vaccine.